Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

850 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. Kirkwood JM, et al. Among authors: ibrahim jg. J Clin Oncol. 2001 May 1;19(9):2370-80. doi: 10.1200/JCO.2001.19.9.2370. J Clin Oncol. 2001. PMID: 11331315 Clinical Trial.
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.
Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB. Kirkwood JM, et al. Among authors: ibrahim j. J Clin Oncol. 2001 Mar 1;19(5):1430-6. doi: 10.1200/JCO.2001.19.5.1430. J Clin Oncol. 2001. PMID: 11230488 Clinical Trial.
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Falkson CI, et al. Among authors: ibrahim j. J Clin Oncol. 1998 May;16(5):1743-51. doi: 10.1200/JCO.1998.16.5.1743. J Clin Oncol. 1998. PMID: 9586887 Clinical Trial.
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R. Kirkwood JM, et al. Among authors: ibrahim j. Cancer. 2002 Sep 1;95(5):1101-12. doi: 10.1002/cncr.10775. Cancer. 2002. PMID: 12209697 Free article. Clinical Trial.
Use and abuse of statistics in evidence-based medicine.
Kirkwood JM, Ibrahim J, Sondak VK, Ernstoff MS, Flaherty L, Haluska FJ. Kirkwood JM, et al. Among authors: ibrahim j. J Clin Oncol. 2002 Oct 1;20(19):4122-3; author reply 4123-4. doi: 10.1200/JCO.2002.99.132. J Clin Oncol. 2002. PMID: 12351612 No abstract available.
Pathologic and gene expression features of metastatic melanomas to the brain.
Hamilton R, Krauze M, Romkes M, Omolo B, Konstantinopoulos P, Reinhart T, Harasymczuk M, Wang Y, Lin Y, Ferrone S, Whiteside T, Bortoluzzi S, Werley J, Nukui T, Fallert-Junecko B, Kondziolka D, Ibrahim J, Becker D, Kirkwood J, Moschos S. Hamilton R, et al. Among authors: ibrahim j. Cancer. 2013 Aug 1;119(15):2737-46. doi: 10.1002/cncr.28029. Epub 2013 May 21. Cancer. 2013. PMID: 23695963 Free PMC article.
850 results